Skip to content
Screener

Edwards Lifesciences EW Cumulative Cost Basis

Cumulative Cost Basis at other companies

Haemonetics logo
HaemoneticsHAE
$854.27M+7.4%
Abbott logo
AbbottABT
Merit Medical Systems logo
Merit Medical SystemsMMSI
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$51.48B+11.6%
Enterprise value$49.74B+11.0%
P/E51.2×+40.1×
P/S7.9×-0.2×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp
FCF margin17.3%

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The source filing: Edwards Lifesciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001099800-26-000026
Held-to-maturityMarch 31, 2026 / Amortized CostMarch 31, 2026 / Gross Unrealized GainsMarch 31, 2026 / Gross Unrealized LossesMarch 31, 2026 / Fair ValueDecember 31, 2025 / Amortized CostDecember 31, 2025 / Gross Unrealized GainsDecember 31, 2025 / Gross Unrealized LossesDecember 31, 2025 / Fair Value
Bank time deposits$39.1$39.1$39.1$39.1
Available-for-sale
Commercial paper$422.7$422.7$452.3$452.3
U.S. government and agency securities257.8(0.4)257.4466.50.2(0.4)466.3
Asset-backed securities36.0(0.5)35.535.6(0.6)35.0
Corporate debt securities516.1(0.7)515.4347.20.1(0.4)346.9
Total$1,232.6$(1.6)$1,231.0$1,301.6$0.3$(1.4)$1,300.5

Item 1. Financial Statements (Unaudited)

FAQ

What is Edwards Lifesciences's cumulative cost basis?
Edwards Lifesciences (EW) reported cumulative cost basis of $1.23B in Q1 2026.
How has Edwards Lifesciences's cumulative cost basis changed year-over-year?
Edwards Lifesciences's cumulative cost basis increased by 48.9% year-over-year, from $827.8M to $1.23B.
What is the long-term trend for Edwards Lifesciences's cumulative cost basis?
Over 5 years (2020 to 2025), Edwards Lifesciences's cumulative cost basis has grown at a 7.1% compound annual growth rate (CAGR), from $924.3M to $1.3B.

Ask your AI about Edwards Lifesciences's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude